Cargando…

Correction for Xiong et al., The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565525/ https://www.ncbi.nlm.nih.gov/pubmed/36201543 http://dx.doi.org/10.1073/pnas.2215628119

Ejemplares similares

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2
por: Xiong, Hualong, et al.
Publicado: (2022)

Protective neutralizing epitopes in SARS‐CoV‐2
por: Liu, Hejun, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
por: Tea, Fiona, et al.
Publicado: (2021)

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
por: Fang, Yan, et al.
Publicado: (2022)

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine
por: Li, Dapeng, et al.
Publicado: (2022)

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
por: Li, Dapeng, et al.
Publicado: (2022)

Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth
por: Deshpande, Suprit, et al.
Publicado: (2023)

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies
por: Xue, Jun-biao, et al.
Publicado: (2021)

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
por: Naranbhai, Vivek, et al.
Publicado: (2022)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

The immunodominant and neutralization linear epitopes for SARS-CoV-2
por: Lu, Shuai, et al.
Publicado: (2021)

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
por: Kurahashi, Yukiya, et al.
Publicado: (2022)

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
por: Yuan, Meng, et al.
Publicado: (2020)

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants
por: Rodriguez-Aponte, Sergio A., et al.
Publicado: (2023)

Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
por: Sun, Dapeng, et al.
Publicado: (2021)

IgV somatic mutation of human anti–SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity
por: de Mattos Barbosa, Mayara Garcia, et al.
Publicado: (2021)

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
por: Wang, Zijun, et al.
Publicado: (2021)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
por: Wang, Zijun, et al.
Publicado: (2022)

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
por: Huang, Kuan-Ying A., et al.
Publicado: (2023)

A human SARS-CoV neutralizing antibody against epitope on S2 protein
por: Duan, Jinzhu, et al.
Publicado: (2005)

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
por: Fu, Dan, et al.
Publicado: (2021)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
por: Nair, Manoj S., et al.
Publicado: (2023)

The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
por: Buck, Amanda M., et al.
Publicado: (2023)

Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
por: Huang, Kuan-Ying A., et al.
Publicado: (2021)

Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
por: Chen, Yuezhou, et al.
Publicado: (2022)

Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2
por: Zhou, Xiaojuan, et al.
Publicado: (2021)

Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020)

Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
por: Zhu, Yufang, et al.
Publicado: (2022)

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
por: Mantus, Grace, et al.
Publicado: (2022)

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
por: Tang, Juanjie, et al.
Publicado: (2021)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_54gakgpg6a97lb9m7pqmu09c3o